News & Updates
Filter by Specialty:
BMI and glycaemic status significantly affect CV risk in patients treated with anthracyclines
A retrospective cohort study of >11,000 Hong Kong patients who initiated anthracycline-based chemotherapy found that both body-mass index (BMI) and glycaemic status significantly affect cardiovascular (CV) risks, with the highest risk observed in those with concurrent obesity and diabetes/prediabetes.
BMI and glycaemic status significantly affect CV risk in patients treated with anthracyclines
24 Jun 2025
Analogue bests human insulin in T2D patients with kidney failure
Analogue insulin demonstrates superiority over human insulin in terms of survival among patients with kidney failure and type 2 diabetes (T2D) who are receiving peritoneal dialysis, according to a study presented at ERA 2025.
Analogue bests human insulin in T2D patients with kidney failure
20 Jun 2025
CONFIDENCE supports simultaneous MR, SGLT2 inhibition in CKD and T2D
The phase II CONFIDENCE* trial shows the benefit of dual therapy with the selective ns-MRA** finerenone and the SGLT2i** empagliflozin vs either agent alone in individuals with chronic kidney disease (CKD) and type 2 diabetes (T2D).
CONFIDENCE supports simultaneous MR, SGLT2 inhibition in CKD and T2D
20 Jun 2025
How does finerenone fare among DKD patients in real life?
In patients with chronic kidney disease and type 2 diabetes who have not been previously treated with any mineralocorticoid receptor antagonist (MRA), the use of finerenone results in marked reductions in albuminuria, reports a study presented at ERA 2025.
